首页> 外文期刊>Biotechnology & Biotechnological Equipment >Protective effects of traditional Chinese herbal formula Compound Xueshuantong Capsule (CXC) on rats with blood circulation disorders
【24h】

Protective effects of traditional Chinese herbal formula Compound Xueshuantong Capsule (CXC) on rats with blood circulation disorders

机译:中药复方血栓通胶囊对血液循环障碍大鼠的保护作用

获取原文
           

摘要

ABSTRACT Compound Xueshuantong Capsule (CXC) is a traditional Chinese herbal formula composed of root of Panax pseudoginseng var. notoginseng (Burkill) G. Hoo & C.L. Tseng, root of Astragalus membranaceus var. mongholicus (Bunge) P.K. Hsiao, root of Salvia miltiorrhiza var. charbonnelii (H. L????v.) C.Y. Wu, and root of Scrophularia ningpoensis Hemsl. CXC was approved by the China Food and Drug Administration in 2003 (No. Z20030017) based on the positive clinical effect in the treatment of cardiovascular diseases. The present study was designed to elucidate the mode of action of CXC in the regulation of the haemorheology, blood coagulation, oxidative stress and energy metabolism. Rats were placed in ice-cold water (0?¢????4???????°C) for 5????min during the time interval (4????h) between two adrenaline injections to induce blood circulation disorders. Blood was collected from abdominal aorta to detect whole blood viscosity, plasma viscosity, maximum platelet aggregation rate, erythrocyte aggregation index, red corpuscle electrophoresis index, activated partial thromboplastin time and prothrombin time. Myocardial tissue was homogenized to detect total antioxidant capacity, myeloperoxidase, Na + ?¢????K + ATPase, and Ca 2+ ATPase. The results indicated that, in addition to preventing haemorheological disorders, CXC could perform anti-platelet and anticoagulant effects, promote total antioxidant capacity and regulate myocardial energy metabolism, which might partly account for its mechanisms of action against cardiovascular diseases.
机译:摘要复方血栓通胶囊(CXC)是由人参变种人参组成的中草药配方。三七(Burkill)G.Hoo&C.L.曾,黄芪的根。蒙古(蹦极)萧,丹参的根。 charbonnelii(H. L ???? v。) Wu和Scrophularia ningpoensis Hemsl的根。由于CXC在治疗心血管疾病方面具有积极的临床效果,因此于2003年获得了中国食品药品监督管理局(Z20030017)的批准。本研究旨在阐明CXC在血液流变学,血液凝结,氧化应激和能量代谢调节中的作用方式。在两次肾上腺素注射之间的时间间隔(4小时)内,将大鼠置于冰冷的水(0℃至4℃)中5分钟。诱发血液循环障碍。从腹主动脉收集血液以检测全血粘度,血浆粘度,最大血小板聚集率,红细胞聚集指数,红细胞电泳指数,活化的部分凝血活酶时间和凝血酶原时间。均质化心肌组织以检测总抗氧化能力,髓过氧化物酶,Na +α+κK+ ATPase和Ca 2+ ATPase。结果表明,除预防血液流变学疾病外,CXC还可以发挥抗血小板和抗凝作用,促进总抗氧化能力并调节心肌能量代谢,这可能部分解释了其对心血管疾病的作用机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号